Abstract: The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.

Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OO1 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OO1 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing ?-rays, ?-rays, ?-rays, neutron radiation, or a combination thereof.

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Abstract: The invention relates to a recombinant adenovirus that expresses endostatin, angiostatin, or a combination of endostatin and angiostatin. The invention also relates to method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of (i) a recombinant adenovirus and (ii) an anti-angiogenic agent to treat the cancer in the subject.

Abstract: The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.

Abstract: The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

Abstract: The invention provides, e.g., a recombinant virus comprising (i) a modified TATA box-based promoter, and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter and/or modified CAAT box-based promoter lacks a functional TATA box and/or CAAT box and permit selective expression of the gene in a hyperproliferative cell. The recombinant viruses can be used to treat cell proliferative diseases and disorders, including certain forms of cancer.

Abstract: The invention provides a recombinant adenovirus comprising two (or more) therapeutic transgenes, e.g., CD80 and CD137L. The transgenes are preferably inserted into an E1b-19K insertion site and/or an E3 insertion site.

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

Abstract: A composition is provided which comprises a recombinant viral particle comprising a capsid, wherein the viral particle is encapsulated into an anionic liposome comprising lecithin and polyethylene glycol (PEG). A method for preparing and purifying the encapsulated viral particles is provided as well. Methods for treating patients by using the encapsulated viral particles are provided as well.

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF? trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Abstract: A composition is provided which comprises a recombinant viral particle comprising a capsid, wherein the viral particle is encapsulated into an anionic liposome comprising lecithin and polyethylene glycol (PEG). A method for preparing and purifying the encapsulated viral particles is provided as well. Methods for treating patients by using the encapsulated viral particles are provided as well.

Abstract: An apparatus for treating lymphedema in the limb of a patient as an outer sleeve configured to encircle the limb of the patient. A plurality of straps are secured in a lateral configuration on the sleeve to tighten the sleeve about the limb of the patient. Detachable markers are located on each of the straps adjacent a reference point on the straps to permit the straps to be tightened, loosened and then retightened to the same positions. The method for treating edema in the limb of a patient at a multiplicity of spaced apart locations comprises encircling the limb of a patient with an elongated sleeve having an elongated open seam and a plurality of spaced apart laterally extending releasable enclosable tightening straps. Strap are closed to secure the sleeve to the patient's limb. One of the straps is released, and a partially air-inflated pneumatic bladder is inserted through the seam underneath the released strap to position the bladder adjacent the patient's limb and the interior of the sleeve.

Abstract: An apparatus for treating lymphedema in the limb of a patient as an outer sleeve configured to encircle the limb of the patient. A plurality of straps are secured in a lateral configuration on the sleeve to tighten the sleeve about the limb of the patient. Detachable markers are located on each of the straps adjacent a reference point on the straps to permit the straps to be tightened, loosened and then retightened to the same positions. The method for treating edema in the limb of a patient at a multiplicity of spaced apart locations comprises encircling the limb of a patient with an elongated sleeve having an elongated open seam and a plurality of spaced apart laterally extending releasable enclosable tightening straps. Strap are closed to secure the sleeve to the patient's limb. One of the straps is released, and a partially air-inflated pneumatic bladder is inserted through the seam underneath the released strap to position the bladder adjacent the patient's limb and the interior of the sleeve.